Biosensors Granted U.S. Patent Covering Drug-Eluting Stent Technology
SINGAPORE, Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- Biosensors International Group, Ltd. (Bloomberg: BIG SP), today announced that on September 6, 2005 it was granted a patent from the United States Patent and Trademark Office covering the technology behind its drug-eluting stents (''DES''). Specifically, this U.S. patent, (Patent Number 6939376) covers the use of anti-restenotic, immuno-suppressive drugs including Everolimus, in combination with a biodegradable drug-release polymer coating on an endovascular stent. The patent was filed in April 2002, and is valid in the U.S. for 20 years from the filing date. The Company has also filed for the same patent in Australia, Japan and Europe, which it is anticipating to receive. ''Intellectual assets are particularly important in a fast growing and competitive segment such as the multi-billion dollar DES market,'' said Yoh-Chie Lu, Chairman and CEO of Biosensors. "We have a strong belief that bioresorbable polymers will be a key factor for the long term success of DES. The positive STEALTH clinical trial results is consistent with this and we believe that the combination therapy, as covered by this patent, will be a step forward in treating coronary artery diseases. Securing a patent that covers a core technology in this area will bring us one step closer to achieving our vision of becoming a leader in DES,'' he said. The DES technology covered by this patent has clinically been shown to reduce restenosis in humans when compared to bare metal stents as demonstrated in the FUTURE I and II, and STEALTH clinical trials conducted by Biosensors. Restenosis is the renarrowing of the coronary arteries following stent implantation. The stent, which is a tiny, expandable mesh-like tube, acts as a scaffold inside the coronary artery and helps keep the artery open after balloon angioplasty. The patent also covers the technology used in the Company's flagship DES, BioMatrix(TM), which uses Biosensors' proprietary Biolimus A9(TM) drug, bioresorbable polymer, S-Stent(TM) and stent delivery catheter, all of which have been developed in-house. Biosensors also has other patents pending on the Biolimus A9TM drug technology. Biosensors believes that this new patent will go a long way in strengthening its intellectual property portfolio. The Company will continue to secure, leverage and when necessary, vigorously defend its intellectual property as it develops more inventions in the medical specialties it addresses. About Biosensors International Group, Ltd. Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a bioresorbable polymer and a proprietary anti-restenotic drug. It is pursuing two separate drug-eluting stent programs, BioMatrix(TM) and Axxion(TM), and has licensed aspects of its drug-eluting stent technology to four companies. Forward Looking Statements Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," ''estimate,'' ''anticipate,'' ''believe,'' ''project'' or ''continue'' or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances. Media Contact Information: Biosensors International Group Ms Tina Lim, Executive, Corporate Communications Tel: +65-6213-5712 Email: firstname.lastname@example.org For investor related enquiries, please write to email@example.com. WeR1 Consultants Pte Ltd Mona Leong Senior Consultant Tel: +65-6737-4844 Hp: +65-9187-4449 Email: firstname.lastname@example.org
SOURCE Biosensors International Group, Ltd.
More by this Source
Biosensors Reports Financial Results for the Third Quarter of Fiscal Year 2014
Feb 12, 2014, 08:01 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.